Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zealand Pharma A/S ADR (NQ: ZEAL )

N/A UNCHANGED
Last Price Updated: 3:24 PM EDT, Sep 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zealand Pharma A/S ADR

< Previous 1 2 Next >
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Polar Capital
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma major shareholder announcement: Van Herk Investments
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move Higher
Zealand Pharma A/S (NASDAQ: ZEAL) has 
Via Benzinga
Recap: Zealand Pharma Q1 Earnings
Zealand Pharma (NASDAQ:ZEAL) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Zealand Pharma Amends Financing Agreement With Oberland Capital
Via Benzinga
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
From Zealand Pharma
Via GlobeNewswire
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Via Benzinga
Recap: Zealand Pharma Q4 Earnings
Zealand Pharma (NASDAQ:ZEAL) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Thursday. 
Via Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for... 
Via Benzinga
Why Zealand Pharma Shares Are Rising
Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies reached new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Zealand Pharma
Zealand Pharma (NASDAQ:ZEAL) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Zealand... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 12, 2022
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter. 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.